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INTRODUCTION     
The natural history of Familial Hypercholestrolaemia 
(FH) has changed with the use of statins, such that 
proper identification and treatment of FH subjects 
through cascade screening (NICE 2018) has resulted in 
normalisation of disease-free survival almost 
approaching that of an age- and gender-matched 
population [1]. Furthermore, coronary artery disease 
(CAD) risk may be significantly attenuated, if 
diagnosed early and properly treated.  
 Genetic analysis of a Northern European 
general population has recently discovered 
approximately 1/200 of the people were with 
heterozygous FH (HeFH). Less than 1% of HeFH are 
detected in most countries, taking into account a 
theoretical estimated global prevalence of 1/500. Albeit 
FH individuals have increased CAD risk by at least 10-
fold, many studies reported failure to achieve 
recommended LDL-C targets in a large proportion of 
these patients. Based on the prevalence of 1/200 and 
1/500 [2, 3], it is estimated that about 14 - 35 million 
individuals worldwide are affected by FH [4, 5]. If left 
untreated, HeFH individuals may develop premature 
CAD (pCAD) at ages of <55 and <60 years, in men and 
women respectively [5].   
 Therefore, individuals are recommended for 
FH screening, if a person or family member presents 
with either (i) FH, (ii) total plasma cholesterol level 
(TC) of ≥8 mmol/L (≥ 310 mg/dL), and/or LDL-C ≥ 5 
mmol/L (≥ 195 mg/dL), in an adult; or TC ≥ 6 mmol/L 
(≥ 230 mg/dL) and/or LDL-C ≥ 4 mmol/L (≥ 155 
mg/dL), in a child, (iii) tendon xanthoma(s) and/or (iv) 
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pCAD or sudden premature cardiac death. Family 
cascade screening and/or screening of high-risk 
individuals, is the most cost-effective way of 
identifying FH cases and initiating early and adequate 
LLT.  
 This review highlights an updated overall 
management of FH, comprising of treatment targets, 
lifestyle measures, optimal treatment combinations in 
adults and children, as well as an overview on newer 
LLT including PCSK9i, microsomal transfer protein 
inhibitor, allele-specific oligonucleotide to ApoB100 
and PCSK9 mRNA. 
 
RISK ESTIMATION 
Recently confirmed new evidence suggests that 
retention of LDL-C and apolipoprotein B (ApoB) 
within the arterial wall is the key factor of atherogenesis 
[6]. Besides, lowering LDL-C and ApoB-containing 
lipoproteins reduces CV events. Furthermore, it has also 
been well documented that hypercholesterolaemia 
causes and is strongly linked to atherosclerotic 
cardiovascular disease (ASCVD). In tandem with these 
new findings, new targets for LDL-C and a revision of 
the CV risk stratification have been proposed by the 
new guidelines, particularly relevant to patients in the 
very-high and high- risk categories. For FH individuals, 
it is unnecessary to perform total risk estimation as they 
are already categorised as high or very-high risk 
individuals. Presence of ASCVD or one other major risk 
factor in FH patients, renders them to be in the very-
high risk category, whilst those without are considered 
to be at high-risk (Figures 1, 2). 
 While the calculation for risk estimation scores 
is not needed for individuals who are already in 
proactive management for their risk factors, several 
groups of individuals have been identified to be in the 
high and very-high total CV risk categories. These 
include those with type 1 and type 2 DM, documented 
ASCVD, chronic kidney disease (CKD) or other high-
level individual risk factors such as severe 
hypercholesterolaemia.  
 
 
 
Figure 1 CV Categories 
 
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, 
Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias: Lipid modification to reduce 
cardiovascular risk - The Task Force for the management of 
dyslipidaemias of the European Society of Cardiology (ESC) and 
European Atherosclerosis Society (EAS). European Heart Journal, 
2019; 41: 111-88.  [41] 
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Figure 2 Recommendations for the detection and treatment of patients with HeFH.  
 
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the management 
of dyslipidaemias: Lipid modification to reduce cardiovascular risk - The Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019; 41: 111-88. [41]. 
 
Some individuals, without requiring risk 
scoring, are categorised in the high- or very-high 
cardiovascular disease (CVD) risk groups, demanding 
the immediate attention of all risk factors. These include 
individuals with known FH, CVD, chronic kidney 
disease (CKD), diabetes mellitus (DM) of long 
duration, as well as the presence of coronary artery 
calcium score (>100 Agatston), carotid or femoral 
plaques, or severely elevated serum Lp(a) levels. Lp(a), 
an LDL-C-like particle that contains a highly variable 
apolipoprotein(a), has been associated with increased 
CV risk [7]. Elevated Lp(a) has also been reported as an 
independent determinant for CVD risk [8]. Therefore, a 
single Lp(a) measurement may assist in identifying 
individuals who inherit very high Lp(a) levels, resulting 
in enhanced ASCVD lifetime risk. Subsequent risk 
stratification of some groups of patients such as those 
with high risk of ASCVD and a strong family history of 
premature CVD, can be further assisted by high Lp(a) 
level. Furthermore, Lp(a) may be useful in ascertaining 
treatment strategies among patients with borderline 
estimated risk categories. 
 
TREATMENT TARGETS: LDL-C  
The recent European guidelines on management of 
dyslipidaemia, have suggested the following 
recommendations for LDL-C targets in FH: (1) 
Children: <3.5 mmol/L (<135 mg/dL), (2) Adults: <1.8 
mmol/L (<100 mg/dL), and <1.4 mmol/L (<70 mg/dL) 
for adults in the very-high-risk category with ASCVD 
or one other major risk factor (Figures 2, 3). 
 In the presence of ASCVD or one other major 
risk factor, FH patients are considered to be at very-high 
risk, therefore, the recommended LDL-C targets are at 
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                           Figure 3 Target LDL-C levels according to risk categories. 
 
                          Reproduced from: Ministry of Health Malaysia, Management of Dyslipidaemia 2017, MOH Malaysia, Editor. 2017,  
                         Ministry of Health: Malaysia. [71]. 
 
 
least 50% reduction from baseline and to achieve <1.4 
mmol/L (<55 mg/dL). In contrast, FH patients without 
ASCVD or another major risk factor, are grouped in the 
high-risk category, with LDL-C targets suggested at 
least 50% reduction from baseline and <1.8 mmol/L 
(<70 mg/dL). Similarly, using the Framingham Risk 
Score (FRS)-General CVD risk stratification tool, FH 
with and without ASCVD are classified as very-high 
and high-risk categories respectively. However, with 
this tool, the recommended LDL-C targets for those risk 
categories are higher at <1.8 and <2.6 mmol/L (Figure 
3).  
 Regardless of age, these targets are relevant for 
both HeFH and homozygous FH (HoFH). However, 
these targets are very challenging to accomplish in 
HoFH with current treatment, both in children and 
adults. Based on a community study in Malaysia, lipid-
lowering therapies (LLT) are prescribed to only 56.6% 
of potential (Definite and Probable) HeFH, according to 
the Dutch Lipid Clinic Network (DLCN) criteria [9]. 
Still, none of them achieved the therapeutic LDL-C 
target for high or very-high risk individuals as 
recommended by the Malaysian National Clinical 
Practice Guidelines for Management of Dyslipidaemia 
[9]. However, in a hospital-based FH cohort, an overall 
of 95.9% of the FH patients received statins, of whom 
only 9.8% achieved the LDL-C target of <1.8 mmol/L 
(Chua et al., 2019, unpublished).  
 Furthermore, our group reported that about 
31% of the hypercholesterolaemic adults in the 
Malaysian community are in the high or very-high risk 
category according to the FRS-General CVD risk 
assessment tool. Of those, only 24.7% were on lipid-
lowering medication, of whom only a mere 16.3% 
achieved target LDL-C for the high and very-high risk 
categories [10].  
 Due to ethical reasons, randomised clinical 
trials of LLT against placebo in FH subjects have not 
been organised, thus, the lack of reports on the benefits 
of LLT. Nonetheless, treatment goals and benefits have 
been well reported in large-scale clinical trials among 
non-FH individuals  [11]. It has been clearly established 
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that with LDL-C as the main goal of treatment, its 
degree of decrement is proportional to the decline in 
both CV and all mortality. For every 1 mmol/L of 
decrement in LDL-C level, there is a corresponding 
decline in CV mortality and total mortality by 20% and 
12% respectively, over 5 years [11]. Hence, all 
untreated FH individuals above 40 years of age, have 
been proposed to be regarded as very-high CV risk 
category, due to exposure to elevated LDL-C levels 
since birth [12]. 
 
LIFESTYLE MEASURES 
In parallel with lowering the elevated LDL-C levels, 
lifestyle intervention has to be intensified and all other 
major risk factors have to be diligently managed 
according to expert recommendations (Figure 4). A 
healthy diet needs to be emphasised, consisting of low 
cholesterol, saturated fats, trans-fat and carbohydrates 
whilst focussing on whole grain products, fish, 
vegetables and fruits, gearing towards ideal body 
weight and waist circumference. Intensive health 
education focussing on lifestyle intervention including 
smoking, physical activity and diet, need to be given to 
all FH patients and their families [13]. A healthy diet 
should be implemented and individualised, with the 
involvement of the whole family and support by a 
certified dietitian. Plant sterols and stanols have been 
reported to lower LDL-c levels to a certain extent, hence 
can be considered as functional foods. 
 
 
Figure 4 Treatment targets and goals for CVD prevention  
 
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the management 
of dyslipidaemias: Lipid modification to reduce cardiovascular risk - The Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019; 41: 111-88. [41]. 
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Figure 5 Recommendations for pharmacological LLT  
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the management 
of dyslipidaemias: Lipid modification to reduce cardiovascular risk - The Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019; 41: 111-88. [41]. 
 
Smoking cessation is extremely important for 
smokers, and where necessary such patients should be 
referred to a specialised anti-smoking programme. It is 
imperative to advise children and young adults to 
abstain from smoking and not be subjected to passive 
smoking. Implementation of regular physical activities 
is crucial. However, assessment of CV function is 
advisable in adults with FH, before starting any 
strenuous exercise programme. Despite the benefits of 
lifestyle intervention, including healthy diets, almost all 
FH patients require LLT to reduce elevated LDL-C. 
PHARMACOTHERAPY 
In adults, treatment with LLT should be started as soon 
as possible, after a diagnosis of FH has been made, in 
tandem with lifestyle intervention. The utilisation of 
imaging techniques such as coronary calcium scoring 
and carotid/femoral plaques assessment is 
recommended to detect asymptomatic atherosclerosis, 
for subsequent improvement of risk assessment. 
 The priority of pharmacotherapy for adults is as 
follows: (i) maximal potent statin dose, (ii) ezetimibe, 
(iii) bile acid sequestrant, (iv) PCSK9i, (v) lipoprotein 
apheresis in HoFH and treatment-resistant HeFH with 
CAD. Treatment with high-intensity statin, in 
combination with ezetimibe in most instances, should 
be initiated as soon as possible. For FH patients in the 
very-high risk category (presence of ASCVD or one 
other major risk factor), if the LDL-C targets are not 
reached despite being on maximally tolerated statin 
dose and ezetimibe, proprotein convertase 
subtilisin/kexin type1 inhibitor (PCSK9i) is 
recommended. If the LDL- target is still not achieved, 
combination of statin with a bile acid sequestrant may 
be considered (Figure 5 and Figure 6). For patients with 
statin intolerance at any dosage (even after rechallenge), 
either ezetimibe alone, or in combination with a 
PCSK9i should be considered.  
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Figure 6: (A) Treatment algorithm for pharmacological LLT. (B) Treatment goals for LDL-C across categories of total CVD risk. 
 
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias: Lipid modification to reduce cardiovascular risk - The Task Force for the management of dyslipidaemias 
of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019; 41: 111-88. 
[41] 
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          Figure 7 Expected clinical benefits of LLT. 
 
Reproduced from:  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.: 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias: Lipid modification to reduce cardiovascular risk - The Task Force for the management of 
dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 
2019; 41: 111-88.  [41]. 
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Figure 8 Kaplan Meyer Survivor curve of CAD-free life between FH individuals who received and not received FH treatments. 
 
Reproduced from: Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al.: Familial 
hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary 
heart disease. European Heart Journal, 2013; 34: 3478-3490.[5]. 
 
 
High-intensity statin at maximal dose, 
including either rosuvastatin 40 mg, atorvastatin 80 mg, 
or pitavastatin 4 mg, should be commenced in adults at 
the first consultative visit (Figure 7). However, due to 
the association with elevated risk for myositis and 
rhabdomyolysis, simvastatin 80 mg is not 
recommended as this dose. There are several 
justifications for the recommendation to initiate 
treatment with maximal dose of a high intensity statin. 
Firstly, while most FH patients need at least 50% LDL-
C reduction, only less than 5% (1/20) of FH individuals 
achieve the targeted LDL-C levels. Secondly, high 
percentage FH patients receive inadequate doses to 
reach LDL-C goals. Thirdly, many clinicians despite 
not achieving treatment targets, fail to increase statin 
doses. 
In children, it is highly recommended to initiate 
LLT at about the age of 6 -10 years, in parallel with 
lifestyle intervention. The priority for pharmacotherapy 
in children is as follows; (i) statin, (ii) ezetimibe, (iii) 
bile acid sequestrant, and (iv) lipoprotein apheresis in 
HoFH. For children, statins to be used should only be 
amongst those licensed statins in this age group, usually 
simvastatin or pravastatin [14, 15].  
Clinical evaluation of response to treatment and 
safety are recommended to be done about 4-6 weeks 
following initiation of therapy. Numerous evidences 
have shown substantial reduction in major CV events 
with statin treatment in observational studies. Thus, 
statins are  the main drugs of choice [11, 16, 17]. 
Furthermore, the introduction of statin treatment has 
also resulted in the decline of CAD events in FH 
patients [18, 19]. Moreover, FH individuals who have 
had treatment initiated prior to onset of CAD, have the 
potential benefit of CAD event-free period as good as 
those in the general population (Figure 8). 
Statins are first-line drugs for patients in the 
high and very-high risk categories, as they have been 
overwhelmingly proven to reduce CV events and safe 
to use by numerous randomised controlled trials. 
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However, in some high-risk individuals such as FH 
patients or those with statin intolerance, the targeted 
LDL-C levels are not achieved despite maximally 
tolerated statin. The use of non-statin therapies, such as 
ezetimibe and the newer PCSK9i have been previously 
reviewed [20]. Most FH patients are unable to achieve 
the targeted LDL-C level with statin alone, albeit 
commencement of the maximal doses of high intensity 
statin. In such situation, ezetimibe can be combined 
with statin therapy with high compliance and minimal 
side effects. Generally, statin–ezetimibe combination 
will result in 60–70% LDL-C reduction. Bile acid 
sequestrants such as cholestyramine, colestipol, or 
colesevelam, is suggested as a third drug for very-high 
risk patients when the LDL-C levels exceeding 
recommended targets of <1.8 mmol/L (<70 mg/dL). 
Addition of pure niacin (up to 3 g/day) on top of the 
above-mentioned medications, in some FH patients, as 
practised in some countries, is another possible option 
to reduce LDL-C and Lp(a) further. Combination of 
maximal dose of high-intensity statin with fibrates can 
be considered in FH patients with 
hypertriglyceridaemia and low HDL-C, or TG >5.7 
mmol/L (>500 mg/dL). This statin combination is 
particularly with fenofibrate, due to its favourable drug 
interaction report [21] and effect on LDL-C reduction 
in FH [22]. Fenofibrate is also an option if there is 
intolerance or unavailability to other LLT, as it is 
capable of reducing LDL-C levels even when TG is 
normal. Further information on management, safety, as 
well as efficacy of LLT have been previously eluded 
[23]. 
Specialised clinical management is needed for 
statin intolerance in FH patients. This is to ascertain that 
wherever possible, the FH patients have been 
challenged with the various types of statins, in addition 
to considering, depending on appropriate cases, 
combination therapy of low dose of statin, ezetimibe, 
and resins. 
 
LIPOPROTEIN APHERESIS  
For severely hypercholesterolaemic individuals with 
very-high CV risk despite already under LLT, 
lipoprotein apheresis (LA) is recommended, especially 
for HoFH children. Up to 50-75% of LDL-C and Lp(a) 
reduction can be achieved with weekly or biweekly 
lipoprotein apheresis session [24-27]. LA is available at 
specialised lipid clinics, haemodialysis centres and 
blood transfusion centres. Different countries may have 
different clinical criteria for initiation of lipoprotein 
apheresis. 
 
HOMOZYGOUS FAMILIAL 
HYPERCHOLESTEROLAEMIA  
HoFH is rarer (1:160 000 – 1:320 000) than HeFH, and 
almost certainly cause early ASCVD death (<30 years 
old) if not treated. Clinical manifestations include 
xanthomata, premature and progressive CVD which 
usually develop before the age of 20 years, and TC level 
of more than 13 mmol/L (>500 mg/dL).  
 It is important to identify the HoFH in young 
age, and critical to initiate intensive LLT by lipid 
specialists, and, when available, with lipoprotein 
apheresis. These early and extensive treatment can lead 
to a 5 - 70% decrement in plasma LDL-C levels, if 
maximally tolerated pharmacological therapy is 
maintained [28]. The detailed guidelines on HoFH 
management is discussed in EAS consensus statements 
[28, 29]. 
Case 1 – Homozygous FH with severe xanthelasma 
Our group has previously reported 3 cases of HoFH. 
The first case was a rare case of HoFH in a 22-year-old 
Malay woman with severe hypercholesterolaemia 
(LDL-C 13.9 mmol/L) and the presence of gross 
xanthelasma [30]. Upon her referral to a Specialist Lipid 
Clinic, she was clinically diagnosed as FH, but without 
personal history of CAD or other major risk factors. 
However, three of her siblings died due to sudden 
cardiac death at young age (20 - 40 years old). Her 
parents have marital consanguinity, where they are 
related (cousins). Genetic testing was done and she was 
confirmed to inherit a homozygous pathogenic variant, 
C255S (c.763T>A) in Exon 5 of the her LDLR gene. 
Family cascade screening was performed on her 
affected family members and confirmed the presence of 
the same disease-causing variant. She was treated with 
high-intensity statins (atorvastatin 40 – 80 mg) and 
ezetimibe, which managed to reduce her LDL-C by 
more than 50% from baseline, although targeted LDL-
C of <2.6 mmol/L was not achieved.  
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Case 2 – Homozygous FH with successful pregnancy 
outcome 
Our second case of HoFH, was first seen with 
complications of severe ASCVD including 
supravalvular aortic stenosis. Despite genetic 
counselling, she decided to proceed on with the 
pregnancy, with subsequent successful pregnancy 
outcome [31]. Pregnancy in HoFH may pose the risk of 
early coronary morbidity and mortality to both foetus 
and mother. Hence, the combination of HoFH and 
pregnancy can be a potentially fatal condition. The 
difficulty of her LDL-C management was exacerbated 
by the fact that statins are contraindicated in pregnancy, 
thus, the choice of LLT was limited. In contrast, LA is 
an alternative effective treatment to control cholesterol 
level during pregnancy. However, the procedure is not 
widely available in the Asian region, especially in 
economically deprived countries. Despite being 
counselled, this patient refused to undergo LA, hence, 
was continued on LLT. Her LDL-C level peaked to 
above 20 mmol/L in the second trimester, during which 
she developed angina symptoms and underwent 
angioplasty. To date, there are scarce documented case 
reports of HoFH in pregnancy, the majority of whom 
underwent LA through-out their pregnancy. This case 
report illustrates a rare but successful pregnancy 
outcome of a HoFH patient, managed by a multi-
disciplinary team, treated with LLT during pregnancy. 
 
Case 3 – Homozygous FH with good response and 
unique legacy effect of PCSK9 Inhibitor 
In this third case of HoFH, our group report a good 
response and a unique prolonged effect of short-term 
alirocumab treatment on a clinically and genetically 
confirmed young HoFH patient, who suffered from 
ACS. The patient was initially treated with a 
combination of high intensity statin and ezetimibe for 
12 weeks. Subsequently, alirocumab was added to the 
lipid-lowering regime, which managed to achieve 
guideline recommended LDL-C target within 10 weeks. 
However, due to financial constraints, alirocumab was 
stopped after 32 weeks of the triple drug combination 
therapy. Interestingly, despite cessation of PCSK9 
inhibitor therapy for period of subsequent 30 weeks, 
LDL-C level only increased slightly, but not returning 
to pre-alirocumab baseline level, and more importantly, 
managed to maintain target LDL-C levels [32]. This 
suggests HoFH patients with residual LDL receptor 
expression as in this case, can benefit from PCSK9 
inhibitor therapy. This case illustrates the hypothesised 
legacy effect of PCSK9 inhibitor, where LDL-C 
reduction may persist for a long time even after 
cessation of the medication. However, the long-term 
clinical benefit is still unclear. 
 
FAMILIAL HYPERCHOLESTEROLAEMIA IN 
CHILDREN  
Children with FH can be effectively diagnosed based on 
clinical features such as severe hypercholesterolaemia, 
a positive family history of hypercholesterolaemia, 
pCAD, and/or genetically confirmed FH mutations [33] 
. LDL-C in childhood can be used for optimal 
discrimination between FH and non-FH due to the lack 
of exposure to secondary causes of hyperlipidaemia. 
The threshold limit of hypercholesterolaemia in 
children with a positive family history of 
hypercholesterolaemia and pCAD is LDL-C of >4.0 
mmol/L (>155 mg/dL). If FH gene mutation is detected 
in a parent, the child LDL-C threshold level is >3.5 
mmol/L (>130 mg/dL). Genetic analysis in children can 
be initiated at 5 years old or even at younger age in 
suspected HoFH cases. Children of mutation-confirmed 
parents have 50% chance of inheriting the gene 
mutation, hence are also recommended to undergo 
genetic testing. [34].  
 Several observational studies in FH children 
have suggested that earlier initiation of LLT can lead to 
LDL-C reduction and improvement in endothelial 
function, better than starting the LLT in later age, where 
the early reduction of LDL-C will subsequently reduce 
coronary outcomes in later years [15, 33, 35, 36]. 
Therapeutic lifestyle changes and statin treatment are 
therapies for FH children, which should be initiated at 
the age of about 6 -10 years. Ten years old children 
should be screened for FH and treated with statins such 
as simvastatin or  pravastatin, which are licensed for this 
age group. [14, 15]. The LLT can be started with low-
dose statin, and gradually increased until the LDL-C 
goal is achieved [37]. For proven FH cases, on a suitable 
diet and LDL >4.0 mmol/L on two occasions, the initial 
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aim of the LLT is to achieve a reduction in plasma LDL-
C by 50%, and subsequent target LDL of <4.0 mmol/L 
in children between the ages of 8 and 10 years. For 
children older than 10 years, an LDL-C goal of <3.5 
mmol/L (<135 mg/dL) should be targeted. 
 Our group has recently reported a rare case of 
FH in a pair of 8-year old identical twins, who were 
identified in a family cascade screening [38]. Their 
baseline LDL-C levels were 8.8 mmol/L and 8.6 
mmol/L respectively, with absence of lipid stigmata 
manifestation. Their father was the index case who 
initially presented with severe hypercholesterolaemia, 
pCAD, positive family history of pCAD, and 
subsequently clinically diagnosed and molecularly 
confirmed as FH. Besides the twins and the father, the 
family cascade screening also managed to clinically 
identify the paternal grandfather, another elder brother, 
aged ten years, a paternal uncle and a cousin as FH 
patients. Genetic analysis by targeted next-generation 
sequencing (NGS) revealed that all these individuals 
were carrying a heterozygous LDLR gene variant which 
was previously described as pathogenic missense 
mutation (c.530C>T). The twins and their elder brother 
were counselled on lifestyle intervention, including 
healthy diet and were started on low dose statin to target 
for at least 50% LDL-C reduction. 
 
NEW TREATMENT MODALITY 
i. PCSK9 Inhibitors 
PCSK9 monoclonal antibodies (mAbs) are the newly 
approved medications for FH therapy which are 
recommended in FH patients in the very-high-risk 
category, if the targeted LDL-C goal is not acquired by 
statin and ezetimibe. Currently, there are only two 
mAbs approved by the Food and Drug Administration 
(FDA): alirocumab and evolocumab. PCSK9i can 
minimise LDL-C levels by up to 60% when co-
administered with statin.  Two randomised controlled 
trials recorded promising therapeutic effect of PCSK9 
treatment in non-FH ASCVD patients [39, 40]. 
PCSK9i. PCSK9i monotherapy is also indicated for FH 
patients who are unable to tolerate statin [29, 41, 42] 
(Figure 6 A). 
 
 
Mechanism of Action 
PCSK9i exert their therapeutic effect by targeting 
PCSK9 protein which is involved in the control of the 
LDL receptor [43]. Physiologically, PCSK9 in plasma 
binds to the LDL receptor and decreases the expression 
of the LDL receptor by fostering lysosomal catabolism 
of the LDL receptor. Consequently, the plasma LDL-C 
level increases. Therefore, a decrease in PCSK9 
concentration or would reduce plasma LDL-C levels 
[44]. PCSK9i reduces the amount of PCSK9 in plasma, 
which in turn decreases its ability to bind to LDL 
receptors. As this association causes intracellular 
degradation of the LDL receptor, reducing circulating 
PCSK9 will increase LDL receptor expression on the 
cell surface. Thus, more circulating LDL-C levels will 
be absorbed by the cells [44]. The optimal effects of 
PCSK9i has been reported when administered together 
with statins, as serum level of PCSK9 is elevated with 
statin treatment [45]. 
 
Effects on Lipids 
Low-density lipoprotein cholesterol 
Alirocumab and evolocumab, either alone or in 
combination with statins and/or other LLTs, in several 
clinical trials, have been reported to dramatically result 
in reduction in LDL-C levels by an average of 60 
percent. If combined with high-intensity or maximally 
tolerated statins, alirocumab and evolocumab lead to 
46-73 percent LDL-C reduction, compared to placebo, 
and 30 percent more than ezetimibe. PCSK9i plus 
ezetimibe decreased LDL-C, even in patients who do 
not tolerate statins [46]. Alirocumab and evolocumab 
have also been reported to attenuate LDL-C levels in 
patients at increased CV risk, especially those with DM. 
[47]. PCSK9i is effective in lowering LDL-C in a wide 
variety of hypercholesterolaemic patients, due to its 
primary action on LDL receptor, as long as patients are 
capable of producing LDL receptors. Patients who may 
benefit from PCSK9i are those with HeFH, and to a 
lesser degree, HoFH patients with residual LDL 
receptor expression. HoFH with receptor deficiency 
responds poorly to therapy [48]. 
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Triglycerides and high-density lipoprotein 
cholesterol 
In addition to being potent in LDL-lowering, PCSK9i 
also decrease TG levels and elevate both HDL-C and 
ApoA-I levels. Treatment with evolocumab results in 
26 percent TG reduction, and 9 percent  and 4 percent 
increment in HDL-C and ApoA respectively, in phase 
II studies; similar results have been reported for 
alirocumab [23, 49]. However, the TG lowering effect 
must be confirmed.in populations with higher initial 
blood TG concentrations.  
 
Lipoprotein(a) 
Contrary to statins, anti-PCSK9 mAB also lowers 
plasma levels of Lp(a) Pooled findings from phase II 
studies have demonstrated that PCSK9i treatment 
resulted  in 30-40% reduction in Lp(a) [50, 51]. Whist 
recent research has attempted to understand the 
different mechanisms, the underlying process remains 
unclear. However, it seems to be dissimilar to statins, 
which also enhance the activity of the LDL receptor but 
do not reduce the levels of circulating Lp(a) in humans. 
Furthermore, in properly designed experiments, the 
relative input of this effect to reduction in 
cardiovascular risk continues to be discussed.   
 
Effect on Cardiovascular Morbidity and 
Mortality 
Phase III studies preliminary results showed that CV 
events reduction was accomplished in tandem with 
LDL-C reduction [52-54]. Two important trials have 
been recently completed: More Cardiovascular 
Outcomes Study on PCSK9 Inhibition in Elevated Risk 
Subjects (FOURIER) and Evaluation of Cardiovascular 
Outcomes After an Acute Coronary Syndrome During 
Treatment with Alirocumab (ODYSSEY Outcomes) 
studies [39, 40]. The two trials were comparable with 
respect to the study design of secondary prevention and 
background treatment. However, the cohorts recruited 
had either stable CAD, peripheral arterial disease 
(PAD), or stroke; or a recent (median 2.6 months) ACS. 
The relative advantage was demonstrated in terms of 
primary endpoints risk reduction by 15-20 percent. The 
follow-up duration of both studies was relatively brief, 
hence, taking into account data from previous statin 
studies showing that LDL reduction could occur only 
after approximately one year [11], suggesting possible 
benefit of longer-term therapy may have been 
underestimated in these studies [40, 54]. 
 In the FOURIER study [39], 27,564 patients 
with atherosclerotic CVD, and LDL-C levels of  > 1.8 
mmol/L (70 mg/dL), who were on statin therapy, were 
randomly allocated to receive either evolocumab or 
placebo. Evolocumab at 48 weeks post-treatment, 
lowered the LDL-C median from 2.38 mmol / L (92 
mg/dL) at baseline to 0.78 mmol / L (30 mg/dL). 
Evolocumab therapy decreased the primary outcome 
risk (composite CV mortality, MI, stroke, 
hospitalisation for unstable angina, or coronary 
revascularization) significantly, after a median follow-
up period of 2.2 years, by 15%, [hazard ratio (HR) 0.85, 
95 % CI 0.79-0.92]. The analysis conducted on the 
period to benefit also revealed a smaller benefit in the 
first year of trial compared to subsequent years, in 
parallel with the meta-analysis statin results reported in 
the Cholesterol Therapy Trialists [6]. The 
randomisation to evolocumab did not reduce CV 
mortality nor all-cause mortality risk in the FOURIER 
study. 
 The ODYSSEY Outcomes trial randomised 
18,924 statin-treated patients, with LDL-C levels > 1.8 
mmol / L (> 70 mg dL), non-HDL cholesterol > 2.6 
mmol/L (> 100 mg dL) or ApoB > 80 mg/dL, following 
hospitalisation with acute MI or dysfunctional angina, 
to alirocumab or placebo injections. Alirocumab 
allocation lowered the baseline mean LDL-C at 12 
months from 2.38 mmol/L (92 mg/dL) to 1.24 mmol/L 
(48 mg/dL). After a median follow-up of 2.8 years, 
there was a relative decline in the primary outcome 
(composite of CAD mortality, non-fatal MI, ischaemic 
stroke, or unstable angina involving hospitalisation) by 
15% (HR 0.85, 95 percent CI 0.78-0.93) [40]. Although 
the ODYSSEY trial demonstrated a substantial decline 
in all-cause mortality, this was an exploratory result and 
was not accompanied by a significant impact on CV 
death. 
Adverse Effects and Interactions 
Anti-PCSK9 mAbs as PCSK9i are administered via 
subcutaneous injection, fortnightly or monthly, at 
different doses depending on the types of agent used. 
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There is absence of potential interaction with 
medications taken orally, as they do not exhibit 
pharmacokinetic or pharmacodynamic interference. 
Itching at the injection site and flu-like signs are among 
the most common reported side effects [55]. Increased 
patient-reported neurocognitive effects have been 
identified in several studies [56]. However, the results 
of a study specifically designed to monitor 
neurocognitive activity, the EBBINGHAUS trial [57],  
has been encouraging, as were the safety findings of 
both the FOURIER and ODYSSEY studies. Mendelian 
randomisation trials have also shown that inhibition of 
PCSK9 can increase the risk of LDL-C-related DM, as 
in the case with statins [58]. However, no signals have 
arisen from clinical trials to date [39, 59, 60]. While 
major long-term PCSK9i studies are essential to 
exclude these and other possible side effects of PCSK9i 
[61], the 7-year results from the IMPROVE-IT research 
showed that chronic low LDL-C levels are not 
correlated with any apparent adverse effects [62]. The 
occurrence of autoantibodies is a possible issue for 
long-term antibody therapy.  
 Evolocumab and alirocumab are both fully 
humanized antibodies and, therefore, theoretically are 
unlikely to activate autoantibodies. Up to now, very few 
anti-drug antibodies have been described, and there has 
been no diminished LDL-C lowering effect. However, 
long term treatment needs to be closely monitored. 
Recently, development for the third anti-PCSK9 mAB, 
a humanised antibody, bococizumab, was ceased due to 
presence of increased neutralizing antibodies resulting 
in diminished LDL-C-lowering effect over time, in 
addition to higher incidence of injection site reactions 
[42]. Furthermore, albeit PCSK9i are effective in 
attenuating LDL-C levels and CV events, in addition to 
statin and/or ezetimibe treatment, taking into account 
financial issues and limited long-term safety data, these 
medications are only probably likely to be considered 
cost-effective in patients in the very-high risk category. 
Hence, their utilisation in economically deprived 
countries may be limited. 
ii. Lomitapide 
In very low-density lipoprotein (VLDL) formation, the 
microsomal triglyceride transfer protein (MTP) 
transmits TGs and phospholipids from the endoplasmic 
reticulum to ApoB. The inhibition of MTP thus inhibits 
both VLDL formation in the liver, as well as 
chylomicrons in the intestines. Lomitapide. an inhibitor 
of MTP is an oral medication for HoFH. Lomitapide 
was evaluated as a supplementary treatment for statins 
with or without apheresis and a reduced-fat diet, in an 
open-label one-arm titration trial, [63]. At 26 and 56 
weeks, LDL-C was reduced from baseline by 50% and 
44% respectively. Lomitapide treatment has been 
demonstrated to reduce frequency of LDL-apheresis in 
patients with HoFH. However, the effect lomitapide on 
CV outcomes has not yet been determined. 
 Lomitapide is associated with elevated levels of 
aminotransferase due to its mechanism of action, which 
most likely represents high liver fat and poor 
gastrointestinal tolerability [63, 64]. The most 
prominent reason for inhibiting dosage increment of 
lomitapide in clinical trials, is the gastrointestinal side 
effects [63]. However, it has been reported that the 
incidence and severity of gastrointestinal side effects 
diminish with time. Therefore, lomitapide treatment 
requires proper patient education and counselling, in 
addition to close monitoring of liver function. 
 
iii. Mipomersen 
Mipomersen, an antisense oligonucleotide capable of 
binding to ApoB-100 messenger RNA (mRNA), hence 
resulting in selective degradation of the mRNA 
molecules, is preferentially transferred to the liver after 
subcutaneous injection. This results in inhibition of 
ApoB protein translation, leading to diminished 
synthesis of  atherogenic lipids and lipoproteins, 
including LDL-C and Lp(a) [65]. Mipomersen, 
clinically indicated for LDL-C lowering in HoFH 
patients, is a supplementary therapy to LLT and diet. 
Albeit officially approved by the US Food and Drug 
Administration (FDA), mipomersen is still not 
registered with the European Medicines Agency 
(EMA). The most frequent adverse effect reported in 
patients on mipomersen therapy is injection site 
reactions [66]. The key safety issues of mipomersen is 
associated with liver toxicity. In addition, mipomersen 
has also be reported to contribute to the development of 
liver steatosis. Mipomersen-treated patients have 
demonstrated greater liver fat from baseline, compared 
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to placebo. [65]. Long-term mipomersen therapy in 
terms of efficacy and safety are currently being 
investigated in patients with statin intolerance and 
serious HeFH.  
 
iv. Inclisiran 
Inclisiran, an experimental drug for LLT, is a 
chemically engineered double-stranded small 
interference ribonucleic acid (RNA) conjugated with 
triantennary N-acetylgalactosamine (GalNAc) to 
promote uptake by hepatocytes. In the hepatocytes, the 
antisense strand is integrated into the ribonucleic acid 
(RNA)-induced silencing complex (RISC) and guides 
the catalytic breakdown of mRNA for PCSK9, hence, 
preventing the translation of the protein PCSK9. The 
decreased intrahepatic PCSK9 increases the recycling 
and expression of LDLR on the hepatocyte cell surface, 
increases LDL-C absorption and reduces circulating 
LDL-C levels [67]. Inclisiran tends to have more 
benefits over PCSK9-directed monoclonal antibodies, 
including its infrequent administration (2 
injections/year vs. 12-26 PCSK9i injections/year) and 
the fact that anti-PCSK9 monoclonal antibodies is a 
challenge at plasma level. Inclisiran, on the other hand, 
acts to mitigate LDL-C and PCSK9 levels at the 
intracellular level of hepatocytes [68]. 
 Recently, a post-hoc review of inclisiran from 
the Phase III, ORION-10, and ORION-11 trials 
revealed an average 54.1 percent decline in LDL-C 
levels after 17 months treatment compared to placebo. 
The data also supported reassuring safety profile and 
efficacy data of inclisiran, with 99 percent of inclisiran-
treated patients exhibiting LDL-C reduction (placebo-
adjusted) of around 30 percent [69]. Inclisiran is 
currently under review by the U.S. Food and Drug 
Administration and the European Medicines Agency for 
the treatment of primary hyperlipidaemia (including 
HeFH) in adults who have elevated LDL-C while being 
on a maximally tolerated dose of statin therapy [70]. 
 
 
 
 
 
CONCLUSION 
This review highlights the overall management, and 
most optimal treatment combinations in HeFH and 
HoFH in adults and children, newer lipid lowering 
medications including PCSK9i, MTP inhibitor, ASO to 
mRNA of ApoB100 and PCSK9. Screening high-risk 
individuals, or cascade family screening, is the most 
cost-effective way of identifying FH cases and initiating 
adequate statin therapy alone or in combination with 
other LLT. In the case of severe FH, where plasma 
LDL-C levels remain high despite maximally-tolerated 
statin and ezetimibe treatment, PCSK9i should be 
considered. 
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